Founded in 1999, SCYNEXIS Inc. (SCYX) is a research-driven biotechnology company focused on the development and commercialization of novel antifungal medications. The company operates primarily in the United States and is headquartered in Durham, North Carolina. SCYNEXIS is committed to transforming the treatment landscape for patients suffering from serious and life-threatening fungal infections.
SCYNEXIS's flagship product is ibrexafungerp (formerly known as SCY-078), an innovative and versatile antifungal agent that is currently being developed for multiple fungal infections under the proprietary name Brexafemme. In June 2021, the Food and Drug Administration (FDA) approved ibrexafungerp for the treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis, a common form of yeast infection. This marked a significant milestone for SCYNEXIS as it is their first approved product. Brexafemme is also the first and only product approved for patients with a demonstrated azole-resistant infection.
Beyond this product, SCYNEXIS is driving development programs to expand its antifungal portfolio. The company is involved in several late-stage clinical trials for a variety of indications, including recurrent and refractory invasive fungal infections and abdominal candidiasis.
SCYNEXIS is fiercely motivated by unmet medical needs, striving to improve patient outcomes in areas of infectious disease that have traditionally had limited treatment options. Their ambition and drive to improve patient health and wellbeing are reflected in their commitment to research and development.
The company operates with a unique blend of scientific rigor and business acumen, having fostered a corporate culture that values scientific innovation, operational efficiency, and meticulous attention to regulatory processes. This balanced approach, coupled with their dedication to developing innovative therapeutics, positions SCYNEXIS well for future growth.
In conclusion, SCYNEXIS Inc. stands as a pioneer in the field of antifungal treatments. It continually extends the boundaries of medical innovation, creating novel solutions for challenging diseases. From the discovery of breakthrough molecules to their development and eventual regulatory approval, SCYNEXIS remains steadfast in its mission to create a healthier world.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
SCYNEXIS, Inc. has appointed Todd Minga, M.D., as Senior Vice President, Research & Development, effective September 14, 2026. Dr. Minga brings over two decades of experience in clinical medicine and drug development, particularly in kidney disease and rare disorders. His expertise will be crucial as SCYNEXIS advances its rare disease development programs, including SCY-770 for autosomal dominant polycystic kidney disease.
SCYNEXIS (NASDAQ: SCYX) has appointed Sanjay Subramanian as its new Chief Financial Officer, effective September 9, 2026, with an annual base salary of $500,000. He will also serve as the principal financial and accounting officer. The outgoing CFO, Ivor Macleod, will remain with the company until October 9 to ensure a smooth transition, and Subramanian's compensation package includes bonuses, equity, and severance terms.
Scynexis Inc. has appointed Sanjay Subramanian as its new Chief Financial Officer, effective September 9, 2026, succeeding the retiring Ivor Macleod. Subramanian brings over 20 years of experience, with his most recent role as CFO at Inozyme Pharma, and is expected to provide strategic insights into Scynexis's financial management and business development, particularly in its focus on severe rare diseases. The market reacted cautiously, with Scynexis's stock falling 4.66% on Nasdaq prior to the announcement.
SCYNEXIS, Inc., a clinical-stage biotechnology company, announced its participation in two upcoming investor conferences in September 2026. The company will hold a fireside chat at the 12th Cantor Global Healthcare Conference and 1x1 investor meetings at the H.C. Wainwright 28th Annual Global Investment Conference. SCYNEXIS focuses on developing therapies for severe and difficult-to-treat diseases, including ADPKD and antifungal treatments.
The vulvovaginal candidiasis treatment market is projected to reach $1.51 billion by 2030, growing at a CAGR of 5.1%, driven by new antifungal medications, personalized therapy, and telehealth. Key players like Pfizer and Mycovia Pharmaceuticals are developing innovative solutions, such as selective oral azole antifungals, to improve treatment outcomes and reduce recurrence. The market is segmented by drug class, administration route, and distribution channels, with ongoing trends focusing on targeted treatments and patient education.
SCYNEXIS, Inc. announced the grant of an inducement equity award to a new Senior Director, effective August 24, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). The award consists of stock options to purchase 20,000 shares at an exercise price of $5.26, vesting over four years. This grant serves as a material inducement for the new employee's acceptance of employment with the clinical-stage biotechnology company.
SCYNEXIS, Inc. (NASDAQ:SCYX) surprised analysts by reporting a statutory profit of US$0.63 per share, significantly exceeding expectations of a loss, and revenues of US$235k. Following these strong quarterly results, analysts have increased their revenue forecasts for 2026 to US$1.73m and reduced the estimated loss per share to US$2.91. Consequently, the consensus price target for SCYNEXIS has risen by 8.9% to US$36.55, indicating an improved outlook from analysts despite a projected revenue decline compared to the wider industry.